Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 61

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 61
---
 625 remaining Series
A Preferred Warrants were exercised into 625 shares of Series A Preferred Stock for gross proceeds of $500,000. During the six months
ended June 30, 2024, no Series A Preferred Warrants were exercised into shares of Series A Preferred Stock.

The Company’s Preferred Warrants were exercisable into Series A Preferred Stock, which had no cash redemption features that required liability treatment. The Company recorded the Preferred Warrants as equity.

February 2025 Pre-funded Warrants and February 2025 Common Warrants

On February 5, 2025, in connection with the February 2025 Offering
(See Note 8), the Company sold (i) 15,000 shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to 112,551 shares of Common
Stock, and (iii) Common Warrants to purchase up to 127,551 shares of common stock, at a combined public offering price of $39.20 per share
and Warrant. During the three months ended March 31, 2025, 91,214 shares of its common stock were issued following the exercise of certain
Pre-Funded Warrants. During the three months ended June 30, 2025, 10,550 shares of its common stock were issued following the exercise
of certain Pre-Funded Warrants. At June 30, 2025, the remaining 10,787 Pre-Funded Warrants remain exercisable. The Pre-Funded Warrants
are exercisable at any time and have no expiration date

Additionally, in connection with the February 2025 Offering, the Company issued the February 2025 Common Warrants to purchase up to 127,551 shares of common stock with an exercise price of $39.20 per share, which are immediately exercisable upon stockholder approval and have a term of exercise equal to five years following date of the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

A summary of outstanding warrants as of June 30, 2025 is as follows:

|                                         |     | Number   
 of       
 Warrants |         |     | Weighted 
 Average  
 Exercise 
 Price    |           |     | Weighted         
 Average          
 Remaining        
 Contractual Life 
 (in years)       |                    |
|